Developer docs
API playgroundTry for free, no card

Search company profiles

Revenio Group Oyj

Full company profile

uuid003eiiy

Namestring
Revenio Group Oyj
Legal namestring
Revenio Group Oyj
Websiteurl
reveniogroup.fi
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Revenio Group Oyj is a Finnish public health technology company (Nasdaq Helsinki: REG1V) headquartered in Vantaa, focused on ophthalmic diagnostic devices and software. Its product portfolio spans intraocular pressure tonometers (iCare IC100, IC200, ST500, HOME2), fundus imaging systems (EIDON AF, DRSplus), the COMPASS combined perimeter and fundus imager, and veterinary tonometry (TONOVET Pro and Plus). Software offerings include the iCare ILLUME AI screening solution for diabetic retinopathy, AMD and glaucoma (powered by RetCAD from the August 2024 Thirona Retina acquisition), iCare CLINIC cloud-based data management, the PATIENT2 patient app for home IOP monitoring, and the Oculo clinical communication and telehealth platform. The May 2026 acquisition of Visionix International (LT International SAS) for EUR 290 million enterprise value added OCT systems, refraction devices, multimodal diagnostic platforms, and lens finishing solutions to the portfolio, taking combined revenue above EUR 250 million and the headcount to over 800.

The company operates a multi-brand go-to-market under the iCare and Visionix brands, distributing products to ophthalmologists, optometrists, and optical retailers in over 100 countries via a hybrid of distributors and direct sales subsidiaries (Icare USA Inc. since 2012; China iCare Medical Technology Co. Ltd. since October 2022). Revenue is generated through four streams: hardware sales of diagnostic devices (the largest contribution), recurring revenue from single-use iCare sensors, software subscriptions (iCare CLINIC, Oculo, ILLUME), and service and support. FY2025 standalone net sales were EUR 109.7 million with an EBIT margin of 23.2%, and the company is regulated under multiple medical device frameworks including EU MDR, ISO 13485, ISO 27001, and MDSAP, providing market access across the EU, US, Canada, Brazil, Japan, and Australia. Major shareholder William Demant Invest (associated with Danish hearing care group Demant) holds 22.4% post-deal; Visionix CEO Marc Abitbol and Charles Vilgrain of Caravelle Capital joined the board as part of the acquisition consideration.

Short descriptiontext

Revenio Group Oyj is a Finnish public health tech company that designs, manufactures, and sells ophthalmic diagnostic devices and software under the iCare and Visionix brands, serving ophthalmologists, optometrists, and optical retailers in over 100 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersVantaa, Finland
HQ citystring
Vantaa
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ophthalmic diagnostic devices, intraocular pressure measurement, fundus imaging systems, optical coherence tomography, ophthalmology software solutions
Industry2 codes
PRIMARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Ophthalmic Goods Merchant Wholesalers423460
SIC code1 code
  • Ophthalmic Goods3851
Product category
Ophthalmic Diagnostic Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Device Sales (iCare and Visionix Brands)
TypeHardware Sales
Description

Sale of ophthalmic diagnostic equipment including tonometers, fundus imaging devices, OCT solutions, perimeters, refraction devices, and accessories. Revenue from device hardware sales through distributors and direct sales network.

reveniogroup.fi
2Sensor Sales (Recurring Revenue)
TypeUsage Based
Description

Sale of single-use sensors for iCare tonometers. Creates recurring revenue stream from consumables used with diagnostic devices.

reveniogroup.fi
3Software Solutions
TypeSubscription Recurring
Description

Clinical software solutions including iCare ILLUME, iCare CLINIC, Oculo platform, and RetCAD AI diagnostics. Software licenses and subscriptions supporting device ecosystem.

reveniogroup.fi
4Service and Support
TypeProfessional Services
Description

Maintenance, calibration, and support services for diagnostic equipment.

tradingview.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Revenio designs, manufactures and sells ophthalmic diagnostic devices and supporting clinical software under the iCare and Visionix brands. Its portfolio includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2, TONOVET Plus/Pro), TrueColor Confocal fundus imaging systems (EIDON AF, DRSplus), the COMPASS perimeter, AI-powered screening (iCare ILLUME, RetCAD), the Oculo cloud-based eye care software platform, and Visionix OCT, refraction, multimodal diagnostic, and finishing solutions. Products are sold to ophthalmologists, optometrists, optical retailers, and veterinary clinics across more than 100 countries through distributors and the company's own sales subsidiaries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Improves diagnostic efficiency and quality of care throughout patient journey
+2 more records
Product overview1 text field

Revenio Group Oyj offers a comprehensive portfolio of ophthalmic diagnostic solutions under the iCare and Visionix brands. The iCare brand includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2), veterinary tonometry (TONOVET Pro, TONOVET Plus), fundus imaging devices (EIDON AF, DRSplus), perimetry systems (COMPASS), and cloud-based software solutions (ILLUME with AI screening, CLINIC, PATIENT2 app). Visionix products include Optical Coherence Tomography (OCT), refraction systems, multimodal diagnostic platforms, and finishing solutions, acquired in 2026. The combined portfolio serves optometry, optical retail, and ophthalmology with devices, imaging solutions, refraction technologies, software, and workflow solutions across over 100 countries. Key AI capability is embedded in iCare ILLUME for automated screening of diabetic retinopathy, AMD, and glaucoma.

Product and service15 records
1iCare IC100
CategoryOphthalmic Diagnostic Devices - Tonometry
Description

Handheld rebound tonometer for measuring intraocular pressure (IOP) in seated or standing patients, used for routine eye pressure measurements and glaucoma screening by eye care professionals.

2iCare IC200
CategoryOphthalmic Diagnostic Devices - Tonometry
Description

Multi-purpose flagship rebound tonometer for clinical, surgical, and emergency use with 200-degree freedom of movement, measuring IOP in any patient position.

3iCare ST500
CategoryOphthalmic Diagnostic Devices - Tonometry
Description

Slit-lamp-mounted tonometer incorporating iCare's rebound technology for efficient and patient-friendly eye pressure measurement, streamlining clinical workflow.

4iCare HOME2
CategoryOphthalmic Diagnostic Devices - Home Tonometry
Description

Home-use eye pressure monitor enabling patients to measure IOP in daily life settings, with data transmitted securely to healthcare providers via the companion PATIENT2 application.

5iCare TONOVET Plus
CategoryVeterinary Ophthalmic Diagnostic Devices
Description

Veterinary rebound tonometer for measuring eye pressure in animal patients, used by veterinarians and animal eye specialists.

6iCare TONOVET Pro
CategoryVeterinary Ophthalmic Diagnostic Devices
Description

Flagship veterinary tonometer with 200-degree positioning freedom, designed for professionals requiring advanced features in accuracy and usability, including surgery and emergency use.

7iCare EIDON AF
CategoryOphthalmic Diagnostic Devices - Fundus Imaging
Description

TrueColor Confocal fundus imaging system with widefield imaging capabilities and fully automated operation, available in three models covering various imaging methods.

8iCare DRSplus
CategoryOphthalmic Diagnostic Devices - Fundus Imaging
Description

Non-mydriatic fundus camera capable of capturing high-quality images from small pupils (2-2.5mm) and through cataracts or media opacities using confocal technology.

9iCare COMPASS
CategoryOphthalmic Diagnostic Devices - Perimetry
Description

Perimeter combining visual field examination with high-resolution confocal fundus imaging in a single device, achieving better reproducibility than existing standards.

10iCare ILLUME
CategoryOphthalmology Software - AI Screening
Description

AI-powered screening solution combining artificial intelligence with TrueColor Confocal fundus imaging for automated detection of diabetic retinopathy, age-related macular degeneration, and glaucoma, with a fully automated workflow and ILLUME Connect for referral sharing.

11Oculo
CategoryOphthalmology Software - Clinical Platform
Description

Australian cloud-based eye care software platform combining clinical communication, telehealth, patient remote monitoring, and data analytics, connecting care teams and electronic medical records with imaging systems.

12Visionix OCT Solutions
CategoryOphthalmic Diagnostic Devices - OCT Imaging
Description

Optical Coherence Tomography equipment providing high-resolution cross-sectional imaging of retinal structures, representing a growing segment newly acquired through the 2026 Visionix merger.

13Visionix Refraction Systems
CategoryOphthalmic Diagnostic Devices - Refraction
Description

Refraction devices and systems for measuring refractive errors of the eye, part of Visionix's complementary product portfolio acquired in 2026 for the optometry and optical retail market.

14Visionix Multimodal Diagnostic Platforms
CategoryOphthalmic Diagnostic Devices - Multimodal
Description

Multimodal diagnostic platforms combining multiple imaging modalities for comprehensive eye examination, part of Visionix's portfolio acquired in 2026.

15Visionix Finishing Solutions
CategoryOphthalmic Equipment - Lens Finishing
Description

Lens finishing solutions for eyewear prescription fulfillment, part of Visionix's comprehensive product portfolio acquired in 2026.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-15
Description

Strategic partnership for screening and reform of optometric care models. The partnership aims to advance eye disease screening and improve optometric treatment approaches.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss ophthalmic device manufacturer with strength in perimetry, slit lamps, tonometry, and imaging. Overlaps with Revenio's COMPASS perimeter and iCare imaging products in the same clinical and academic eye care channels.

TypeEmerging player
Description

US-based AI eye-screening company (EyeArt) providing autonomous diabetic retinopathy detection. Directly competes with RetCAD/iCare ILLUME AI screening workflows in optometry and primary care channels.

TypeBroad incumbent
Description

Global ophthalmic medtech leader with surgical, vision care, and growing diagnostic/imaging offerings. Competes with Revenio's broader ophthalmic portfolio across channels and has substantially greater scale and R&D budget.

4Topcon Corporation
TypeDirect peer
Description

Major Japanese manufacturer of OCT devices, fundus cameras, and ophthalmic diagnostic equipment, with a strong direct-sales network and optometry channel presence. Closely comparable to Revenio/Visionix in OCT and screening product categories serving optometrists and ophthalmologists globally.

TypeDirect peer
Description

Italian fundus camera and perimeter manufacturer acquired by Revenio in 2019; relevant as a directly comparable niche diagnostic imaging player now subsumed into the combined entity.

TypeDirect peer
Description

German manufacturer of diagnostic imaging devices including OCT, fundus imaging, and perimetry systems. Directly competes with Revenio's imaging and perimetry products, with strong specialist/ophthalmology presence in Europe and global reach.

7Carl Zeiss Meditec AG
TypeBroad incumbent
Description

One of the largest ophthalmic diagnostic and surgical device manufacturers globally, with extensive OCT, fundus imaging, and refractive product lines. Directly overlaps with Revenio's iCare and Visionix portfolios and competes for the same optometry and ophthalmology customers worldwide.

TypeDirect peer
Description

Japanese maker of ophthalmic diagnostic devices including OCT, fundus cameras, tonometers, and refractive equipment. Directly competes with Revenio's iCare tonometers and Visionix refraction devices across global optical retail and ophthalmology channels.

TypeEmerging player
Description

Israeli developer of handheld prenatal ultrasound; comparable as a healthcare diagnostic device company in which board member Anat Loewenstein has involvement, illustrating adjacent diagnostic device business models relevant to Revenio's growth pattern.

TypeDirect peer
Description

Manufacturer of ultra-widefield retinal imaging devices (optomap) competing directly with iCare EIDON AF and DRSplus fundus cameras in optometry, optical retail, and screening settings worldwide.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries7 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Revenio Group Oyj

Ophthalmic Diagnostic Devicesreveniogroup.fi

Revenio Group Oyj is a Finnish public health tech company that designs, manufactures, and sells ophthalmic diagnostic devices and software under the iCare and Visionix brands, serving ophthalmologists, optometrists, and optical retailers in over 100 countries.

What Revenio Group Oyj does

Revenio Group Oyj is a Finnish public health technology company (Nasdaq Helsinki: REG1V) headquartered in Vantaa, focused on ophthalmic diagnostic devices and software. Its product portfolio spans intraocular pressure tonometers (iCare IC100, IC200, ST500, HOME2), fundus imaging systems (EIDON AF, DRSplus), the COMPASS combined perimeter and fundus imager, and veterinary tonometry (TONOVET Pro and Plus). Software offerings include the iCare ILLUME AI screening solution for diabetic retinopathy, AMD and glaucoma (powered by RetCAD from the August 2024 Thirona Retina acquisition), iCare CLINIC cloud-based data management, the PATIENT2 patient app for home IOP monitoring, and the Oculo clinical communication and telehealth platform. The May 2026 acquisition of Visionix International (LT International SAS) for EUR 290 million enterprise value added OCT systems, refraction devices, multimodal diagnostic platforms, and lens finishing solutions to the portfolio, taking combined revenue above EUR 250 million and the headcount to over 800.

The company operates a multi-brand go-to-market under the iCare and Visionix brands, distributing products to ophthalmologists, optometrists, and optical retailers in over 100 countries via a hybrid of distributors and direct sales subsidiaries (Icare USA Inc. since 2012; China iCare Medical Technology Co. Ltd. since October 2022). Revenue is generated through four streams: hardware sales of diagnostic devices (the largest contribution), recurring revenue from single-use iCare sensors, software subscriptions (iCare CLINIC, Oculo, ILLUME), and service and support. FY2025 standalone net sales were EUR 109.7 million with an EBIT margin of 23.2%, and the company is regulated under multiple medical device frameworks including EU MDR, ISO 13485, ISO 27001, and MDSAP, providing market access across the EU, US, Canada, Brazil, Japan, and Australia. Major shareholder William Demant Invest (associated with Danish hearing care group Demant) holds 22.4% post-deal; Visionix CEO Marc Abitbol and Charles Vilgrain of Caravelle Capital joined the board as part of the acquisition consideration.

Revenio Group Oyj firmographics

Firmographics
Name
Revenio Group Oyj
Legal name
Revenio Group Oyj
Website
https://reveniogroup.fi
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
101–250 employees
Short description
Revenio Group Oyj is a Finnish public health tech company that designs, manufactures, and sells ophthalmic diagnostic devices and software under the iCare and Visionix brands, serving ophthalmologists, optometrists, and optical retailers in over 100 countries.
Ownership category
akta.pro rank

Revenio Group Oyj industry classification

Industry
Product category
Ophthalmic Diagnostic Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
SIC
Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAD
Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAFAKAI
Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging)

Keywords

  • Ophthalmic diagnostic devices
  • Intraocular pressure measurement
  • Fundus imaging systems
  • Optical coherence tomography
  • Ophthalmology software solutions

Where Revenio Group Oyj is headquartered

Location

Headquarters

HQ city
Vantaa
HQ country
Finland
HQ region
Europe

Offices2 records

Markets served

Revenio Group Oyj business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales (iCare and Visionix Brands): Sale of ophthalmic diagnostic equipment including tonometers, fundus imaging devices, OCT solutions, perimeters, refraction devices, and accessories. Revenue from device hardware sales through distributors and direct sales network.
  2. Sensor Sales (Recurring Revenue): Sale of single-use sensors for iCare tonometers. Creates recurring revenue stream from consumables used with diagnostic devices.
  3. Software Solutions: Clinical software solutions including iCare ILLUME, iCare CLINIC, Oculo platform, and RetCAD AI diagnostics. Software licenses and subscriptions supporting device ecosystem.
  4. Service and Support: Maintenance, calibration, and support services for diagnostic equipment.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Revenio Group Oyj product offering

Product offering

Core offering

Revenio designs, manufactures and sells ophthalmic diagnostic devices and supporting clinical software under the iCare and Visionix brands. Its portfolio includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2, TONOVET Plus/Pro), TrueColor Confocal fundus imaging systems (EIDON AF, DRSplus), the COMPASS perimeter, AI-powered screening (iCare ILLUME, RetCAD), the Oculo cloud-based eye care software platform, and Visionix OCT, refraction, multimodal diagnostic, and finishing solutions. Products are sold to ophthalmologists, optometrists, optical retailers, and veterinary clinics across more than 100 countries through distributors and the company's own sales subsidiaries.

Product overview

Revenio Group Oyj offers a comprehensive portfolio of ophthalmic diagnostic solutions under the iCare and Visionix brands. The iCare brand includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2), veterinary tonometry (TONOVET Pro, TONOVET Plus), fundus imaging devices (EIDON AF, DRSplus), perimetry systems (COMPASS), and cloud-based software solutions (ILLUME with AI screening, CLINIC, PATIENT2 app). Visionix products include Optical Coherence Tomography (OCT), refraction systems, multimodal diagnostic platforms, and finishing solutions, acquired in 2026. The combined portfolio serves optometry, optical retail, and ophthalmology with devices, imaging solutions, refraction technologies, software, and workflow solutions across over 100 countries. Key AI capability is embedded in iCare ILLUME for automated screening of diabetic retinopathy, AMD, and glaucoma.

Differentiator

Problem solved

Functional benefit

Products and services

  • iCare IC100 Handheld rebound tonometer for measuring intraocular pressure (IOP) in seated or standing patients, used for routine eye pressure measurements and glaucoma screening by eye care professionals.
  • iCare IC200 Multi-purpose flagship rebound tonometer for clinical, surgical, and emergency use with 200-degree freedom of movement, measuring IOP in any patient position.
  • iCare ST500 Slit-lamp-mounted tonometer incorporating iCare's rebound technology for efficient and patient-friendly eye pressure measurement, streamlining clinical workflow.
  • iCare HOME2 Home-use eye pressure monitor enabling patients to measure IOP in daily life settings, with data transmitted securely to healthcare providers via the companion PATIENT2 application.
  • iCare TONOVET Plus Veterinary rebound tonometer for measuring eye pressure in animal patients, used by veterinarians and animal eye specialists.
  • iCare TONOVET Pro Flagship veterinary tonometer with 200-degree positioning freedom, designed for professionals requiring advanced features in accuracy and usability, including surgery and emergency use.
  • iCare EIDON AF TrueColor Confocal fundus imaging system with widefield imaging capabilities and fully automated operation, available in three models covering various imaging methods.
  • iCare DRSplus Non-mydriatic fundus camera capable of capturing high-quality images from small pupils (2-2.5mm) and through cataracts or media opacities using confocal technology.
  • iCare COMPASS Perimeter combining visual field examination with high-resolution confocal fundus imaging in a single device, achieving better reproducibility than existing standards.
  • iCare ILLUME AI-powered screening solution combining artificial intelligence with TrueColor Confocal fundus imaging for automated detection of diabetic retinopathy, age-related macular degeneration, and glaucoma, with a fully automated workflow and ILLUME Connect for referral sharing.
  • Oculo Australian cloud-based eye care software platform combining clinical communication, telehealth, patient remote monitoring, and data analytics, connecting care teams and electronic medical records with imaging systems.
  • Visionix OCT Solutions Optical Coherence Tomography equipment providing high-resolution cross-sectional imaging of retinal structures, representing a growing segment newly acquired through the 2026 Visionix merger.
  • Visionix Refraction Systems Refraction devices and systems for measuring refractive errors of the eye, part of Visionix's complementary product portfolio acquired in 2026 for the optometry and optical retail market.
  • Visionix Multimodal Diagnostic Platforms Multimodal diagnostic platforms combining multiple imaging modalities for comprehensive eye examination, part of Visionix's portfolio acquired in 2026.
  • Visionix Finishing Solutions Lens finishing solutions for eyewear prescription fulfillment, part of Visionix's comprehensive product portfolio acquired in 2026.

Quantifiable outcome

  • Improves diagnostic efficiency and quality of care throughout patient journey
  • +2 more outcomes

Companies that use Revenio Group Oyj

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Revenio Group Oyj technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Revenio Group Oyj partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • iCare, epitop, bon OpticminorStrategic or Co-development Partner · 15 January 2026Strategic partnership for screening and reform of optometric care models. The partnership aims to advance eye disease screening and improve optometric treatment approaches.

Scale indicators9 records

Recent moves12 records

Expansion highlights8 records

Revenio Group Oyj competitors and assessment

Company assessment

Direct peers

  • Haag-Streit Group: Swiss ophthalmic device manufacturer with strength in perimetry, slit lamps, tonometry, and imaging. Overlaps with Revenio's COMPASS perimeter and iCare imaging products in the same clinical and academic eye care channels.
  • Topcon Corporation: Major Japanese manufacturer of OCT devices, fundus cameras, and ophthalmic diagnostic equipment, with a strong direct-sales network and optometry channel presence. Closely comparable to Revenio/Visionix in OCT and screening product categories serving optometrists and ophthalmologists globally.
  • Centervue (now part of Revenio): Italian fundus camera and perimeter manufacturer acquired by Revenio in 2019; relevant as a directly comparable niche diagnostic imaging player now subsumed into the combined entity.
  • Heidelberg Engineering GmbH: German manufacturer of diagnostic imaging devices including OCT, fundus imaging, and perimetry systems. Directly competes with Revenio's imaging and perimetry products, with strong specialist/ophthalmology presence in Europe and global reach.
  • Nidek Co., Ltd. Japanese maker of ophthalmic diagnostic devices including OCT, fundus cameras, tonometers, and refractive equipment. Directly competes with Revenio's iCare tonometers and Visionix refraction devices across global optical retail and ophthalmology channels.
  • Optos plc: Manufacturer of ultra-widefield retinal imaging devices (optomap) competing directly with iCare EIDON AF and DRSplus fundus cameras in optometry, optical retail, and screening settings worldwide.

Emerging players

  • Eyenuk, Inc. US-based AI eye-screening company (EyeArt) providing autonomous diabetic retinopathy detection. Directly competes with RetCAD/iCare ILLUME AI screening workflows in optometry and primary care channels.
  • Pulsenmore Ltd. Israeli developer of handheld prenatal ultrasound; comparable as a healthcare diagnostic device company in which board member Anat Loewenstein has involvement, illustrating adjacent diagnostic device business models relevant to Revenio's growth pattern.

Broad incumbents

  • Alcon Inc. Global ophthalmic medtech leader with surgical, vision care, and growing diagnostic/imaging offerings. Competes with Revenio's broader ophthalmic portfolio across channels and has substantially greater scale and R&D budget.
  • Carl Zeiss Meditec AG: One of the largest ophthalmic diagnostic and surgical device manufacturers globally, with extensive OCT, fundus imaging, and refractive product lines. Directly overlaps with Revenio's iCare and Visionix portfolios and competes for the same optometry and ophthalmology customers worldwide.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenio Group Oyj social profiles

Digital presence

Revenio Group Oyj compliance and trust

Trust signal

Compliance4 records

Revenio Group Oyj financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Revenio Group Oyj leadership team

Management profile

Number of profiles

Profiles6 records

Revenio Group Oyj subsidiaries and ownership

Company hierarchy

Subsidiaries7 records

Revenio Group Oyj funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Revenio Group Oyj M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Revenio Group Oyj

What does Revenio Group Oyj do?

Revenio designs, manufactures and sells ophthalmic diagnostic devices and supporting clinical software under the iCare and Visionix brands. Its portfolio includes handheld and slit-lamp tonometers (IC100, IC200, ST500, HOME2, TONOVET Plus/Pro), TrueColor Confocal fundus imaging systems (EIDON AF, DRSplus), the COMPASS perimeter, AI-powered screening (iCare ILLUME, RetCAD), the Oculo cloud-based eye care software platform, and Visionix OCT, refraction, multimodal diagnostic, and finishing solutions. Products are sold to ophthalmologists, optometrists, optical retailers, and veterinary clinics across more than 100 countries through distributors and the company's own sales subsidiaries.

Is Revenio Group Oyj a public or private company?

Revenio Group Oyj is a public company. It is classified as public and is currently operating.

When was Revenio Group Oyj founded?

Revenio Group Oyj was founded in 2009. It employs 101 to 250 people.

Where is Revenio Group Oyj based?

Revenio Group Oyj is headquartered in Vantaa, Finland, in the Europe region.

How does Revenio Group Oyj make money?

Four revenue lines are on record. Medical Device Sales (iCare and Visionix Brands) is the primary driver. The others are sensor Sales (Recurring Revenue), software Solutions and service and Support.

Who are Revenio Group Oyj's main competitors?

Direct peers on record are Haag-Streit Group, Topcon Corporation, Centervue (now part of Revenio), Heidelberg Engineering GmbH, Nidek Co., Ltd. and Optos plc. Emerging players are Eyenuk, Inc. and Pulsenmore Ltd.. Broad incumbents are Alcon Inc. and Carl Zeiss Meditec AG.

Does Revenio Group Oyj have an API?

No public API is recorded for Revenio Group Oyj.

What industry is Revenio Group Oyj in?

Revenio Group Oyj's product category is Ophthalmic Diagnostic Devices. Its primary akta.pro industry code is HLAHAJAD, Optical Dispensing & Eyewear Devices (Frames, Lenses, Lens Edging/Finishing Equipment), with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewRevenio Group Corporation (REG1V) CEO Acquires 1,400 SharesCEO Jouni Toijala acquired 1,400 Revenio Group shares on November 13 at a volume-weighted average price of €9.3257 per share. The transaction is an isolated insider purchase, with no prior-period comparison provided.KauppalehtiRevenion talousjohtaja osti osakkeita 100 000 eurollaJukka Kainulainen, Revenion CEO, bought 11,099 shares at an average price of 9.01 euros, totaling 100,002 euros. He had not previously owned Revenion shares and started as CEO in August.TradingViewRevenio Group Corporation (REG1V) CFO Acquires 11,099 Shares for €100.0KCFO Jukka Kainulainen acquired 11,099 shares of Revenio Group Corporation on November 13 at a volume-weighted average price of €9.01 per share, totaling approximately €100,000. The disclosure provides no prior-period comparison or context on the CFO's total holdings.KauppalehtiPÖRSSI: Teknosektorin myllerrys heilutti Nokiaa – Revenio rysähtiNokia's stock fell 1.4% on Helsinki's stock exchange, while Revenio dropped 10.7% after its adjusted operating result grew less than expected and revenue missed forecasts. Kamux rose on a revenue beat but a weaker adjusted operating result. The market's OMXH index rose 0.2%.TradingViewRevenio Group: Scale doubled, but flat organic sales and regional headwinds narrowed FY guidanceRevenio Group reported Q3 sales of €58.8m after an acquisition, with organic sales flat and adjusted EBITDA rising over 30% year-over-year. The company narrowed its FY sales guidance to €190m–€200m due to APAC weakness and North American reorganization effects.TradingViewRevenio Group: Acquisition-led sales doubled; integration and balance-sheet strengthening advancedRevenio Group reported Q3 sales more than doubled after the Visionix acquisition, with organic sales flat and adjusted EBITA rising 30.3%. The company narrowed its 2026 sales guidance to EUR 190m–200m and oversubscribed an EUR 80m rights issue.KauppalehtiPÖRSSI: Reveniolle kylmää kyytiä pörssissäHelsinki stock opened lower on Thursday, with Nokia down 2.9% and Revenio down 7.2% after cutting revenue guidance. Revenio cited integration costs from a Visionix acquisition, while Kamux warned of lower adjusted operating profit. Siemens opened higher on strong order growth.KauppalehtiRevenion Visionix kyberhyökkäyksen kohteenaRevenio's French subsidiary Visionix suffered a cyberattack on an internal IT server, prompting immediate containment measures. Revenio says the attack had no impact on other operations and has notified French authorities.TalouselamaTuloskausi kääntyy loppusuoralle: tällä viikolla vuorossa Mandatum ja RevenioHelsinki stock market companies Mandatum and Revenio will report results this week, continuing the Q4 earnings season. The US October CPI data and the recent US midterm election results are also key market drivers. The election outcome may reduce political uncertainty and support markets in the future.KauppalehtiTuloskausi kääntyy loppusuoralle: tällä viikolla vuorossa Mandatum ja RevenioMandatum and Revenio will report earnings this week, with Mandatum reporting Tuesday and Revenio Wednesday. US inflation data and the recent US midterm election results are also key market drivers. Danske Bank forecasts both above- and below-trend inflation at 0.3% monthly pace.